Loading…
Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial
Objectives Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine...
Saved in:
| Published in: | HIV medicine 2019-11, Vol.20 (10), p.691-698 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93 |
| container_end_page | 698 |
| container_issue | 10 |
| container_start_page | 691 |
| container_title | HIV medicine |
| container_volume | 20 |
| creator | Alejos, B Stella‐Ascariz, N Montejano, R Rodriguez‐Centeno, J Schwimmer, C Bernardino, JI Rodes, B Esser, S Goujard, C Sarmento‐Castro, R De Miguel, R Esteban‐Cantos, A Wallet, C Raffi, F Arribas, JR |
| description | Objectives
Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)‐naïve HIV‐positive adults.
Methods
A cross‐sectional study of 201 randomly selected participants who had stored samples available was carried out. We measured telomere length (i.e. the relative telomere length, calculated as the telomere to single copy gene ratio) at baseline with monochrome quantitative multiplex polymerase chain reaction (PCR). We used multivariable predictive linear regression to calculate mean differences and 95% confidence intervals (CIs) for the association between baseline telomere length and baseline characteristics.
Results
The baseline characteristics of the 201 participants did not differ from those of the 805 participants in the parent trial population: 89% were male, the mean age was 39 years, 83.6% were Caucasian, 93% acquired HIV infection via sexual transmission, the mean estimated time since HIV diagnosis was 2.1 years, the mean HIV‐1 RNA load was 4.7 log10 HIV‐1 RNA copies/mL, the mean nadir and baseline CD4 counts were 301 and 324 cells/μL, respectively, and the mean CD4:CD8 ratio was 0.4. In the univariate analysis, shorter telomere length was associated with older age (per 10 years) (P |
| doi_str_mv | 10.1111/hiv.12791 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2293976434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2293976434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93</originalsourceid><addsrcrecordid>eNp1kU1uFDEQRlsIREJgwQWQJTaw6Iz_2t1ejkIgkaJECoFty21XM47cdmN7BmXHEdhxjBwiN-EkODOBBRK1qSrp6alUX1W9JPiQlFqs7OaQ0FaSR9U-4aKrCZXs8XbmNRWC7lXPUrrGmLRM4qfVHiMNoxLT_ernO8gQJ-uVzwmFEQ0uBIMyuDBBBOTAf8krZD0qgI2QY9jYqBzKEVSewOdf3394dXe7AXRy-rksc0g227LOKmar7bw1g4_BOTD3prwCdH68vELloMXy_PIjIpwh7ay3emu2yj2vnozKJXjx0A-qT--Pr45O6rOLD6dHy7Nas64jddPiUQg-jLzVzQiG68E0QmHRddLgEQvaGM4HQgY9AnSSS90YSRtQgzJYS3ZQvdl55xi-riHlfrJJg3PKQ1innpZPylZwxgv6-h_0OqyjL9f1lGHWNhJzVqi3O0rHkFKEsZ-jnVS86Qnu79PqS1r9Nq3CvnowrocJzF_yTzwFWOyAb9bBzf9NfXn9Tvkbi92iHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2303759043</pqid></control><display><type>article</type><title>Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Alejos, B ; Stella‐Ascariz, N ; Montejano, R ; Rodriguez‐Centeno, J ; Schwimmer, C ; Bernardino, JI ; Rodes, B ; Esser, S ; Goujard, C ; Sarmento‐Castro, R ; De Miguel, R ; Esteban‐Cantos, A ; Wallet, C ; Raffi, F ; Arribas, JR</creator><creatorcontrib>Alejos, B ; Stella‐Ascariz, N ; Montejano, R ; Rodriguez‐Centeno, J ; Schwimmer, C ; Bernardino, JI ; Rodes, B ; Esser, S ; Goujard, C ; Sarmento‐Castro, R ; De Miguel, R ; Esteban‐Cantos, A ; Wallet, C ; Raffi, F ; Arribas, JR ; NEAT 001/ANRS 143 Study Group ; the NEAT 001/ANRS 143 Study Group</creatorcontrib><description>Objectives
Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)‐naïve HIV‐positive adults.
Methods
A cross‐sectional study of 201 randomly selected participants who had stored samples available was carried out. We measured telomere length (i.e. the relative telomere length, calculated as the telomere to single copy gene ratio) at baseline with monochrome quantitative multiplex polymerase chain reaction (PCR). We used multivariable predictive linear regression to calculate mean differences and 95% confidence intervals (CIs) for the association between baseline telomere length and baseline characteristics.
Results
The baseline characteristics of the 201 participants did not differ from those of the 805 participants in the parent trial population: 89% were male, the mean age was 39 years, 83.6% were Caucasian, 93% acquired HIV infection via sexual transmission, the mean estimated time since HIV diagnosis was 2.1 years, the mean HIV‐1 RNA load was 4.7 log10 HIV‐1 RNA copies/mL, the mean nadir and baseline CD4 counts were 301 and 324 cells/μL, respectively, and the mean CD4:CD8 ratio was 0.4. In the univariate analysis, shorter telomere length was associated with older age (per 10 years) (P < 0.001), HIV‐1 RNA ≥ 100 000 copies/mL (P = 0.001), CD4 count < 200 cells/μL (P = 0.037), lower CD4:CD8 ratio (P = 0.018), statin treatment (P = 0.004), and current alcohol consumption (P = 0.035). In the multivariable analysis, older age (P < 0.001) and HIV RNA ≥ 100 000 copies/mL (P = 0.054) were independently associated with shorter telomere length.
Conclusions
Both age and HIV RNA viral load correlated with shorter blood telomere length in untreated persons living with HIV. These results suggest that HIV infection and age have synergistic and independent impacts upon immunosenescence.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/hiv.12791</identifier><identifier>PMID: 31532902</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Age ; Aged ; aging ; Alcoholic beverages ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Blood ; CD4 antigen ; CD8 antigen ; Confidence intervals ; Cross-Sectional Studies ; Darunavir - therapeutic use ; Disease transmission ; Emtricitabine ; Emtricitabine - therapeutic use ; Female ; HIV ; HIV infection ; HIV Infections - drug therapy ; HIV Infections - genetics ; Human immunodeficiency virus ; Humans ; Immunosenescence ; Infections ; Logistic Models ; Male ; Mathematical analysis ; Middle Aged ; Polymerase chain reaction ; Raltegravir Potassium - therapeutic use ; Regression analysis ; Ribonucleic acid ; Ritonavir ; Ritonavir - therapeutic use ; RNA ; RNA, Viral - analysis ; Sexual transmission ; Sexually transmitted diseases ; Statistical analysis ; STD ; Telomere ; telomere length ; Tenofovir ; Tenofovir - therapeutic use ; viral load ; Yeast</subject><ispartof>HIV medicine, 2019-11, Vol.20 (10), p.691-698</ispartof><rights>2019 British HIV Association</rights><rights>2019 British HIV Association.</rights><rights>HIV Medicine © 2019 British HIV Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93</citedby><cites>FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93</cites><orcidid>0000-0001-9571-6471</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31532902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alejos, B</creatorcontrib><creatorcontrib>Stella‐Ascariz, N</creatorcontrib><creatorcontrib>Montejano, R</creatorcontrib><creatorcontrib>Rodriguez‐Centeno, J</creatorcontrib><creatorcontrib>Schwimmer, C</creatorcontrib><creatorcontrib>Bernardino, JI</creatorcontrib><creatorcontrib>Rodes, B</creatorcontrib><creatorcontrib>Esser, S</creatorcontrib><creatorcontrib>Goujard, C</creatorcontrib><creatorcontrib>Sarmento‐Castro, R</creatorcontrib><creatorcontrib>De Miguel, R</creatorcontrib><creatorcontrib>Esteban‐Cantos, A</creatorcontrib><creatorcontrib>Wallet, C</creatorcontrib><creatorcontrib>Raffi, F</creatorcontrib><creatorcontrib>Arribas, JR</creatorcontrib><creatorcontrib>NEAT 001/ANRS 143 Study Group</creatorcontrib><creatorcontrib>the NEAT 001/ANRS 143 Study Group</creatorcontrib><title>Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Objectives
Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)‐naïve HIV‐positive adults.
Methods
A cross‐sectional study of 201 randomly selected participants who had stored samples available was carried out. We measured telomere length (i.e. the relative telomere length, calculated as the telomere to single copy gene ratio) at baseline with monochrome quantitative multiplex polymerase chain reaction (PCR). We used multivariable predictive linear regression to calculate mean differences and 95% confidence intervals (CIs) for the association between baseline telomere length and baseline characteristics.
Results
The baseline characteristics of the 201 participants did not differ from those of the 805 participants in the parent trial population: 89% were male, the mean age was 39 years, 83.6% were Caucasian, 93% acquired HIV infection via sexual transmission, the mean estimated time since HIV diagnosis was 2.1 years, the mean HIV‐1 RNA load was 4.7 log10 HIV‐1 RNA copies/mL, the mean nadir and baseline CD4 counts were 301 and 324 cells/μL, respectively, and the mean CD4:CD8 ratio was 0.4. In the univariate analysis, shorter telomere length was associated with older age (per 10 years) (P < 0.001), HIV‐1 RNA ≥ 100 000 copies/mL (P = 0.001), CD4 count < 200 cells/μL (P = 0.037), lower CD4:CD8 ratio (P = 0.018), statin treatment (P = 0.004), and current alcohol consumption (P = 0.035). In the multivariable analysis, older age (P < 0.001) and HIV RNA ≥ 100 000 copies/mL (P = 0.054) were independently associated with shorter telomere length.
Conclusions
Both age and HIV RNA viral load correlated with shorter blood telomere length in untreated persons living with HIV. These results suggest that HIV infection and age have synergistic and independent impacts upon immunosenescence.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>aging</subject><subject>Alcoholic beverages</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Blood</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Confidence intervals</subject><subject>Cross-Sectional Studies</subject><subject>Darunavir - therapeutic use</subject><subject>Disease transmission</subject><subject>Emtricitabine</subject><subject>Emtricitabine - therapeutic use</subject><subject>Female</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunosenescence</subject><subject>Infections</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Mathematical analysis</subject><subject>Middle Aged</subject><subject>Polymerase chain reaction</subject><subject>Raltegravir Potassium - therapeutic use</subject><subject>Regression analysis</subject><subject>Ribonucleic acid</subject><subject>Ritonavir</subject><subject>Ritonavir - therapeutic use</subject><subject>RNA</subject><subject>RNA, Viral - analysis</subject><subject>Sexual transmission</subject><subject>Sexually transmitted diseases</subject><subject>Statistical analysis</subject><subject>STD</subject><subject>Telomere</subject><subject>telomere length</subject><subject>Tenofovir</subject><subject>Tenofovir - therapeutic use</subject><subject>viral load</subject><subject>Yeast</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kU1uFDEQRlsIREJgwQWQJTaw6Iz_2t1ejkIgkaJECoFty21XM47cdmN7BmXHEdhxjBwiN-EkODOBBRK1qSrp6alUX1W9JPiQlFqs7OaQ0FaSR9U-4aKrCZXs8XbmNRWC7lXPUrrGmLRM4qfVHiMNoxLT_ernO8gQJ-uVzwmFEQ0uBIMyuDBBBOTAf8krZD0qgI2QY9jYqBzKEVSewOdf3394dXe7AXRy-rksc0g227LOKmar7bw1g4_BOTD3prwCdH68vELloMXy_PIjIpwh7ay3emu2yj2vnozKJXjx0A-qT--Pr45O6rOLD6dHy7Nas64jddPiUQg-jLzVzQiG68E0QmHRddLgEQvaGM4HQgY9AnSSS90YSRtQgzJYS3ZQvdl55xi-riHlfrJJg3PKQ1innpZPylZwxgv6-h_0OqyjL9f1lGHWNhJzVqi3O0rHkFKEsZ-jnVS86Qnu79PqS1r9Nq3CvnowrocJzF_yTzwFWOyAb9bBzf9NfXn9Tvkbi92iHw</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Alejos, B</creator><creator>Stella‐Ascariz, N</creator><creator>Montejano, R</creator><creator>Rodriguez‐Centeno, J</creator><creator>Schwimmer, C</creator><creator>Bernardino, JI</creator><creator>Rodes, B</creator><creator>Esser, S</creator><creator>Goujard, C</creator><creator>Sarmento‐Castro, R</creator><creator>De Miguel, R</creator><creator>Esteban‐Cantos, A</creator><creator>Wallet, C</creator><creator>Raffi, F</creator><creator>Arribas, JR</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9571-6471</orcidid></search><sort><creationdate>201911</creationdate><title>Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial</title><author>Alejos, B ; Stella‐Ascariz, N ; Montejano, R ; Rodriguez‐Centeno, J ; Schwimmer, C ; Bernardino, JI ; Rodes, B ; Esser, S ; Goujard, C ; Sarmento‐Castro, R ; De Miguel, R ; Esteban‐Cantos, A ; Wallet, C ; Raffi, F ; Arribas, JR</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>aging</topic><topic>Alcoholic beverages</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Blood</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Confidence intervals</topic><topic>Cross-Sectional Studies</topic><topic>Darunavir - therapeutic use</topic><topic>Disease transmission</topic><topic>Emtricitabine</topic><topic>Emtricitabine - therapeutic use</topic><topic>Female</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunosenescence</topic><topic>Infections</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Mathematical analysis</topic><topic>Middle Aged</topic><topic>Polymerase chain reaction</topic><topic>Raltegravir Potassium - therapeutic use</topic><topic>Regression analysis</topic><topic>Ribonucleic acid</topic><topic>Ritonavir</topic><topic>Ritonavir - therapeutic use</topic><topic>RNA</topic><topic>RNA, Viral - analysis</topic><topic>Sexual transmission</topic><topic>Sexually transmitted diseases</topic><topic>Statistical analysis</topic><topic>STD</topic><topic>Telomere</topic><topic>telomere length</topic><topic>Tenofovir</topic><topic>Tenofovir - therapeutic use</topic><topic>viral load</topic><topic>Yeast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alejos, B</creatorcontrib><creatorcontrib>Stella‐Ascariz, N</creatorcontrib><creatorcontrib>Montejano, R</creatorcontrib><creatorcontrib>Rodriguez‐Centeno, J</creatorcontrib><creatorcontrib>Schwimmer, C</creatorcontrib><creatorcontrib>Bernardino, JI</creatorcontrib><creatorcontrib>Rodes, B</creatorcontrib><creatorcontrib>Esser, S</creatorcontrib><creatorcontrib>Goujard, C</creatorcontrib><creatorcontrib>Sarmento‐Castro, R</creatorcontrib><creatorcontrib>De Miguel, R</creatorcontrib><creatorcontrib>Esteban‐Cantos, A</creatorcontrib><creatorcontrib>Wallet, C</creatorcontrib><creatorcontrib>Raffi, F</creatorcontrib><creatorcontrib>Arribas, JR</creatorcontrib><creatorcontrib>NEAT 001/ANRS 143 Study Group</creatorcontrib><creatorcontrib>the NEAT 001/ANRS 143 Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alejos, B</au><au>Stella‐Ascariz, N</au><au>Montejano, R</au><au>Rodriguez‐Centeno, J</au><au>Schwimmer, C</au><au>Bernardino, JI</au><au>Rodes, B</au><au>Esser, S</au><au>Goujard, C</au><au>Sarmento‐Castro, R</au><au>De Miguel, R</au><au>Esteban‐Cantos, A</au><au>Wallet, C</au><au>Raffi, F</au><au>Arribas, JR</au><aucorp>NEAT 001/ANRS 143 Study Group</aucorp><aucorp>the NEAT 001/ANRS 143 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2019-11</date><risdate>2019</risdate><volume>20</volume><issue>10</issue><spage>691</spage><epage>698</epage><pages>691-698</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Objectives
Our aim was to investigate factors associated with baseline blood telomere length in participants enrolled in NEAT 001/ANRS 143, a randomized, open‐label trial comparing ritonavir‐boosted darunavir (DRV/r) plus raltegravir (RAL) with DRV/r plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in antiretroviral therapy (ART)‐naïve HIV‐positive adults.
Methods
A cross‐sectional study of 201 randomly selected participants who had stored samples available was carried out. We measured telomere length (i.e. the relative telomere length, calculated as the telomere to single copy gene ratio) at baseline with monochrome quantitative multiplex polymerase chain reaction (PCR). We used multivariable predictive linear regression to calculate mean differences and 95% confidence intervals (CIs) for the association between baseline telomere length and baseline characteristics.
Results
The baseline characteristics of the 201 participants did not differ from those of the 805 participants in the parent trial population: 89% were male, the mean age was 39 years, 83.6% were Caucasian, 93% acquired HIV infection via sexual transmission, the mean estimated time since HIV diagnosis was 2.1 years, the mean HIV‐1 RNA load was 4.7 log10 HIV‐1 RNA copies/mL, the mean nadir and baseline CD4 counts were 301 and 324 cells/μL, respectively, and the mean CD4:CD8 ratio was 0.4. In the univariate analysis, shorter telomere length was associated with older age (per 10 years) (P < 0.001), HIV‐1 RNA ≥ 100 000 copies/mL (P = 0.001), CD4 count < 200 cells/μL (P = 0.037), lower CD4:CD8 ratio (P = 0.018), statin treatment (P = 0.004), and current alcohol consumption (P = 0.035). In the multivariable analysis, older age (P < 0.001) and HIV RNA ≥ 100 000 copies/mL (P = 0.054) were independently associated with shorter telomere length.
Conclusions
Both age and HIV RNA viral load correlated with shorter blood telomere length in untreated persons living with HIV. These results suggest that HIV infection and age have synergistic and independent impacts upon immunosenescence.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31532902</pmid><doi>10.1111/hiv.12791</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9571-6471</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2019-11, Vol.20 (10), p.691-698 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2293976434 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Age Aged aging Alcoholic beverages Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Blood CD4 antigen CD8 antigen Confidence intervals Cross-Sectional Studies Darunavir - therapeutic use Disease transmission Emtricitabine Emtricitabine - therapeutic use Female HIV HIV infection HIV Infections - drug therapy HIV Infections - genetics Human immunodeficiency virus Humans Immunosenescence Infections Logistic Models Male Mathematical analysis Middle Aged Polymerase chain reaction Raltegravir Potassium - therapeutic use Regression analysis Ribonucleic acid Ritonavir Ritonavir - therapeutic use RNA RNA, Viral - analysis Sexual transmission Sexually transmitted diseases Statistical analysis STD Telomere telomere length Tenofovir Tenofovir - therapeutic use viral load Yeast |
| title | Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20of%20blood%20telomere%20length%20in%20antiretroviral%20treatment%E2%80%90na%C3%AFve%20HIV%E2%80%90positive%20participants%20enrolled%20in%20the%20NEAT%20001/ANRS%20143%20clinical%20trial&rft.jtitle=HIV%20medicine&rft.au=Alejos,%20B&rft.aucorp=NEAT%20001/ANRS%20143%20Study%20Group&rft.date=2019-11&rft.volume=20&rft.issue=10&rft.spage=691&rft.epage=698&rft.pages=691-698&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/hiv.12791&rft_dat=%3Cproquest_cross%3E2293976434%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3881-570f664bf47c5fed4cbd56a06889d0f0625d44b11bcfee8949c5d925eabad0c93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2303759043&rft_id=info:pmid/31532902&rfr_iscdi=true |